Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase IIb study of adjuvant durvalumab in stage IV colorectal cancer with no evidence of disease
2020-001588-10Phase 2Active
- Sponsor
- IRCCS-A.O.U. SAN MARTINO-IST
- Start
- Aug 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in colorectal cancer (CRC) and colon adenocarcinoma (2 arms), sponsored by IRCCS-A.O.U. SAN MARTINO-IST. Primary endpoint: Disease-free survival. Started Aug 2021; status: active.
02
Drugs
durvalumab
03
Conditions
colorectal cancer (CRC)colon adenocarcinoma
Beyond the preview
Go deeper on 2020-001588-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001588-10.